Erythropoietin and Pediatric Cardiac Surgery

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can cause damage to those organs. We hypothesize that a single dose of erythropoietin prior to the heart bypass portion of surgery may protect the infant human heart and brain from injury.

This randomized clinical trial will involve 120 children, age 6 weeks to 18 years, requiring heart bypass surgery for congenital heart defects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240

Congenital Heart Disease Hypoplastic Left Heart Syndrome Transposition of the Great Arteries +1 more

COMPLETED PHASE1/PHASE2

Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial

NCT02564796

Cyanotic Congenital Heart Disease Anemia Cyanosis +1 more

TERMINATED PHASE2

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953

Infant, Premature Erythropoietin Brain Injury +4 more

TERMINATED PHASE2

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

NCT01235923

Preterm Infants

COMPLETED PHASE2

Does Erythropoietin Improve Outcome in Very Preterm Infants?

NCT00413946

Intracranial Hemorrhage Periventricular Leukomalacia Cerebral Palsy +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can cause damage to those organs. A medicine already used in humans, erythropoietin, may protect the heart and brain of children born with heart defects during their surgical repair. In a rabbit model, erythropoietin did protect the hearts. We hypothesize that a single dose of erythropoietin prior to the heart bypass portion of surgery may protect the infant human heart and brain from injury.

For this randomized control trial, 120 children, age 6 weeks to 18 years, requiring heart bypass surgery for congenital heart defects, will be divided into four groups. Two groups will be children whose usual blood oxygen level is low because of their heart defect; the other two will be children with normal blood oxygen levels. Each child will be randomized to receive either erythropoietin or placebo 15 minutes prior to stopping the heart during their surgery.

Erythropoietin's protective function will be measured after surgery by: (1) amount of medication required to support heart function, (2) how well the heart pumps blood as seen by echocardiogram, (3) levels of chemicals produced by the body when heart or brain tissue injury occurs, (4) urine output and oxygen levels (5) time on ventilator support (6) ICU stay and (7) hospital stay. Heart tissue will be collected during surgery to determine how erythropoietin protects heart cells.

Statistical tests including ANOVA will test for similarities and differences among the groups on the measures of protection from injury.

Note - the study design was edited after the FDA released a warning about the use of erythropoietin. Only acyanotic patients were recruited therefore only 2 study groups are included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Heart Defect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3

acyanotic placebo

Group Type PLACEBO_COMPARATOR

acyanotic placebo

Intervention Type DRUG

Single dose IV push

4

acyanotic erythropoietin

Group Type EXPERIMENTAL

acyanotic erythropoietin

Intervention Type DRUG

Single dose IV push

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acyanotic erythropoietin

Single dose IV push

Intervention Type DRUG

acyanotic placebo

Single dose IV push

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 6 weeks to 18 years
* Requiring open heart surgery for congenital heart defect -Parents able to speak English and document informed consent -

Exclusion Criteria

* Received erythropoietin within past 30 days
* Previous adverse reaction to erythropoietin or to albumin
* History of neurological disorder -Laboratory evidence of kidney or liver dysfunction -

Minimum Eligible Age

6 Weeks

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No